登录

Huadao Bio-Medical Lands $14 Million In Series B Financing

Mailman 2019-08-05 22:57

Huadao Bio-Medical just received around 14 million dollars in Series B financing, this round of financing was led by NKY Pharma. The funds will be used for technological innovation and development of CAR-T drug, and the improvement of the company's drug production abilities.

 

Huadao Bio-Medical was founded in 2017, its products include leukemia, digestive tract tumors and other tumors treatment; it is also a pharmaceutical company with CAR-T industry technology. At present, Huadao Bio-Medical just finished CAR-T production equipment preparation and development of liquid nitrogen storage equipment.

 

This project will improve the technology independent of the Chinese companies in the field of CAR-T drug development, and can greatly improve cancer patients' lives around the world.

 

>>>>

About NKY Pharma


Nanjing King-friend Biochemical Pharmaceutical is focused on research, production, and sales of raw material medicines of heparin sodium. It mainly produces a series of products including heparin sodium and low molecular heparin.


Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09